Accepted Manuscript

Title: Effects of AF3442

[N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide],
a novel inhibitor of human microsomal prostaglandin E
synthase-1, on prostanoid biosynthesis in human monocytes in
vitro

Authors: Annalisa Bruno, Luigia Di Francesco, Isabella
Coletta, Giorgina Mangano, Maria Alessandra Alisi, Lorenzo
Polenzani, Claudio Milanese, Paola Anzellotti, Emanuela
Ricciotti, Melania Dovizio, Andrea Di Francesco, Stefania
Tacconelli, Marta L Capone, Paola Patrignani

PII: S0006-2952(09)00975-7
DOI: doi:10.1016/j.bcp.2009.11.011
Reference: BCP 10383

To appear in: *BCP*

Received date: 1-10-2009
Revised date: 6-11-2009
Accepted date: 9-11-2009

Please cite this article as: Bruno A, Di Francesco L, Coletta I, Mangano G, Alisi MA, Polenzani L, Milanese C, Anzellotti P, Ricciotti E, Dovizio M, Di Francesco A, Tacconelli S, Capone ML, Patrignani P, Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.11.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro

Annalisa Bruno^{a,§}, Luigia Di Francesco^{a,§}, Isabella Coletta^b, Giorgia Mangano^b, Maria Alessandra Alisi^b, Lorenzo Polenzani^b, Claudio Milanese^b, Paola Anzellotti^a, Emanuela Ricciotti^{a,1}, Melania Dovizio^a, Andrea Di Francesco^a, Stefania Tacconelli^a, Marta L Capone^a, and Paola Patrignani^{a,*}.

^aDepartment of Medicine and Center of Excellence on Aging, School of Medicine, “G. d’Annunzio” University and “G. d’Annunzio” University Foundation, Ce.S.I., Chieti 66100, Italy.

^bR&D Angelini Research Center, Santa Palomba-Pomezia, 00040 Rome, Italy.

¹Present address: Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, USA

[§]Annalisa Bruno and Luigia Di Francesco contributed equally

***Corresponding author:**

Paola Patrignani, Ph.D, Department of Medicine and Center of Excellence on Aging, School of Medicine, “G. d’Annunzio” University and Ce.S.I., Via dei Vestini, 31, 66100 Chieti, Italy; Tel.: +39-0871-541473, Fax: +39-0871-3556718; E-mail: ppatrignani@unich.it

Abbreviations:

mPGES-1, microsomal prostaglandin(PG)E synthase-1; LPS, *E. coli* lipopolysaccharide; TX, thromboxane; COX, cyclooxygenase; AF3442, [*N*-(9-ethyl-9*H*-carbazol-3-yl)-2-(trifluoromethyl)benzamide]; AA, arachidonic acid; PGI₂, prostacyclin; cPGES, cytosolic PGE synthase; tNSAIDs, traditional non-steroidal anti-inflammatory drugs; GI, gastrointestinal; MAPEG, membrane-associated proteins involved in eicosanoid and glutathione metabolism; TXS, TX synthase; PMSF, phenylmethylsulfonyl fluoride; FCS, Fetal Calf Serum; TBS, tris-buffered saline; SDS-PAGE, sodium dodecyl sulphate - polyacrylamide gel electrophoresis.

Abstract

Inhibitors of microsomal prostaglandin(PG)E synthase-1(mPGES-1) are being developed for the relief of pain. Redirection of the PGH₂ substrate to other PG synthases, found both in vitro and in vivo, in mPGES-1 knockout mice, may influence their efficacy and safety. We characterized the contribution of mPGES-1 to PGH₂ metabolism in lipopolysaccharide(LPS)-stimulated isolated human monocytes and whole blood by studying the synthesis of prostanoids [PGE₂, thromboxane(TX)B₂, PGF_{2α} and 6-keto-PGF_{1α}] and expression of cyclooxygenase(COX)-isozymes and down-stream synthases in the presence of pharmacological inhibition by the novel mPGES-1 inhibitor AF3442 [*N*-(9-ethyl-9*H*-carbazol-3-yl)-2-(trifluoromethyl)benzamide]. AF3442 caused a concentration-dependent inhibition of PGE₂ in human recombinant mPGES-1 with an IC₅₀ of 0.06μM. In LPS-stimulated monocytes, AF3442 caused a concentration-dependent reduction of PGE₂ biosynthesis with an IC₅₀ of 0.41μM. At 1μM, AF3442 caused maximal selective inhibitory effect of PGE₂ biosynthesis by 61±3.3%(mean±SEM, P<0.01 versus DMSO vehicle) without significantly affecting other prostanoids (i.e., TXB₂, PGF_{2α} and 6-keto-PGF_{1α}). In LPS-stimulated whole blood, AF3442 inhibited in a concentration-dependent fashion inducible PGE₂ biosynthesis with an IC₅₀ of 29μM. A statistically significant inhibition of mPGES-1 activity was detected at 10 and 100μM (38±14%, P<0.05, and 69±5%, P<0.01, respectively). Up to 100μM, the other prostanoids were not significantly affected. In conclusion, AF3442 is a selective mPGES-1 inhibitor which reduced monocyte PGE₂ generation also in the presence of plasma proteins. Pharmacological inhibition of mPGES-1 did not translate into redirection of PGH₂ metabolism towards other terminal PG synthases in monocytes. The functional relevance of this observation deserves to be investigated in vivo.

Keywords: mPGE synthase-1, PGE₂, monocytes, inflammation, human whole blood

1. Introduction

Prostanoids are biologically active derivatives of arachidonic acid(AA) released from membrane phospholipids by phospholipases [1]. AA is transformed into prostaglandin(PG)H₂, through the activity of cyclooxygenase(COX) enzymes (i.e. COX-1 and COX-2), and subsequently PGH₂ is metabolized by terminal synthases to the biologically active prostanoids, i.e. prostacyclin(PGI₂), PGD₂, PGF_{2α}, PGE₂ and thromboxane(TX)A₂ [1]. In particular, the isomerization of PGH₂ to PGE₂ is catalyzed by three different isomerases: a cytosolic PGE synthase(cPGES) and two membrane-bound PGESs, mPGES-1 and mPGES-2 [2]. Of these isomerases, cPGES and mPGES-2 are constitutive enzymes whereas mPGES-1 is mainly an induced isoform.

Several lines of evidence suggest that the mechanism of action of traditional non-steroidal anti-inflammatory drugs(tNSAIDs) and NSAIDs selective for COX-2 (named coxibs) for the treatment of pain and inflammatory joint disease, is mainly through the inhibition of COX-2-dependent PGE₂ [3]. Inhibition of constitutively expressed COX-1 in gastrointestinal(GI) tract and presumably in platelets by tNSAIDs seems to play a role in increased risk of upper GI bleeding/perforation [4]. In fact, coxibs which spare COX-1 are associated with lower GI toxicity [3]. Although the inhibition of COX-2-dependent PGE₂ generation by tNSAIDs and coxibs is effective in ameliorating symptoms of inflammation and pain, a small but consistent increased risk of myocardial infarction has been detected in NSAID users [5, 6, 7]. Such adverse reactions are probably linked to the inhibition of COX-2-derived PGI₂ in vascular endothelial cells in the absence of an almost complete and persistent inhibition of platelet COX-1-derived TXA₂ [5, 6, 7]. Thus, a great interest is in the development of new anti-inflammatory drugs with a safer profile. Inhibitors of mPGES-1 are being developed for relief of pain - similarly to NSAIDs - but with the potential advantage of not affecting or perhaps causing a beneficial impact on the cardiovascular system [8, 9]. Inhibitors of mPGES-1 might circumvent adverse GI side-effects of unselective COX inhibitors. However, in the stomachs of mice lacking mPGES-1 a shift from PGE₂ to all other prostanoids, i.e. TXA₂, PGD₂, PGF_{2α}, and PGI₂, was detected thus making extremely difficult to predict the clinical consequences of mPGES-

1 inhibition in the GI tract [10]. Further studies addressing this issue in appropriate animal models
2 are required.

3
4 mPGES-1 belongs to the MAPEG(membrane-associated proteins involved in eicosanoid and
5 glutathione metabolism) superfamily [11]. Similar to COX-2, mPGES-1 is highly up-regulated by
6
7 proinflammatory stimuli and participates in elevated PGE₂ generation in inflammation [11]. It is
8
9 functionally coupled with COX-2 [12], but differences in the promoter region between mPGES-1
10
11 and COX-2 [13] suggest divergent transcriptional mechanisms responsible for the inducible
12
13 regulation of COX-2 and mPGES-1.

14
15 Deletion of mPGES-1 is associated with a profound inhibition of PGE₂ in vitro and in vivo and with
16
17 a redirection of the PGH₂ substrate to other PG synthases, such as PGI₂ and PGD₂, which might
18
19 participate to the safe cardiovascular profile [8, 9]. Discrepant results have been found on the
20
21 possible shift of PGH₂ metabolism to TXA₂ [8, 14]. Whether redirection of PGH₂ metabolism
22
23 towards other PG synthases might be influenced by the extent of reduction of mPGES-1 and by
24
25 cell-specific features is unknown.

26
27 Development of biomarkers to predict drug responses is useful for a rational selection of doses for
28
29 efficacy and toxicity. Endogenous mediators of inflammation might be used as biomarkers for
30
31 therapeutic effects [15, 16]. Thus, the assessment of COX-2 inhibition by the evaluation of PGE₂
32
33 levels in whole blood in response to *E. coli* lipopolysaccharide (LPS) (an index of inducible COX-2
34
35 activity in monocytes) both in vitro and ex vivo (i.e. after dosing) [15, 17] is considered a promising
36
37 biomarker of drug response (analgesia, anti-inflammatory effects) in humans [15, 16]. In fact, it has
38
39 been shown that inhibition of LPS-induced PGE₂ by approximately 80% is sufficient to translate
40
41 into clinical efficacy (analgesia) in humans [15].

42
43 The design, synthesis and characterization of a series of carbazole benzamides led us to the
44
45 identification of several mPGES-1 inhibitors, among which AF3442[N-(9-ethyl-9H-carbazol-3-yl)-
46
47 2-(trifluoromethyl)benzamide] was identified as a lead compound and selected for further
48
49 characterization [18].

1 In the present study we aimed to characterize the contribution of mPGES-1 to PGH₂ metabolism in
2 LPS-stimulated isolated human monocytes and whole blood by studying the synthesis of
3
4 prostanoids and expression of COX-isozymes and down-stream synthases in the presence of
5
6 pharmacological inhibition by AF3442. We choose to study the effect of the compound in human
7
8 monocytes because they represent an important cell-target of the clinical efficacy of mPGES-1
9
10 inhibitors. Interestingly, we found that inhibition of PGE₂ generation at clinically relevant ranges
11
12 was not associated with any significant change of other prostanoids in human monocytes in vitro.
13
14
15
16
17 The functional relevance of this observation deserves to be investigated in vivo.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. Materials and Methods

2.1. Materials

AF3442 (Figure 1) was synthesized and characterized in the Angelini Research Center [18]. MK-886 (3-[1-(4-chlorobenzyl)-3-*t*-butyl-thio-5-isopropylindol-2-yl]-2, 2-dimethylpropanoic acid) was purchased from Calbiochem (San Diego, CA, USA). RPMI-1640 and fetal calf serum (FCS) were purchased from GIBCO-Invitrogen (Carlsbad, CA, USA). Interleukin-1 β (IL-1 β), penicillin/streptomycin, L-glutamine, LPS (derived from *Escherichia Coli* 026:B6), anti-rabbit peroxidase-conjugated IgG were from Sigma-Aldrich (St. Louis, MO, USA). PGH₂ substrate, COX-1, mPGES-1, mPGES-2, cPGES, TXS, PGIS polyclonal antibodies were from Cayman Chemical (Ann Arbor, MI, USA); β -actin and anti-goat peroxidase-conjugated IgG were purchased from Santa Cruz (USA). COX-2 polyclonal antibody was kindly provided by Dr Stacia Kargman from Merk Frosst (Canada). Nucleofector Kit T was from Lonza (Cologne, AG, Germany). Ficoll-Paque and ECL plus were from GE Healthcare Life Sciences (Bucks, UK). Polyvinylidene fluoride (PVDF) membrane was purchased from Bio-Rad Laboratories (Hercules, CA).

2.2. Cloning and expression of human mPGES-1 in A549 cells

Cloning of human mPGES-1 was performed isolating mRNA from A549 (human lung adenocarcinoma) cells cultured in RPMI-1640 supplemented with 2% (v/v) FCS and stimulated with IL-1 β (10ng/ml) for 24 h. It was reverse transcribed into cDNA. Polymerase Chain Reaction amplification was then performed with specific primers [5'-CGGATCCGCCACCATGCCTGCCCACAGCCTG -3' (FW) and 5'-GCTCTAGAGTCACAGGTGGCGGGCCGC -3' (REV) containing BamHI and XbaI restriction sites respectively] and fragments of the expected 459 bp size were obtained, ligated in the bacterial expression vector pcDNA3.1 and transformed into JM109 competent cells. Plasmids were isolated and miniprep products from a few colonies were subjected to restriction analysis that confirmed the presence of the expected fragment pattern. Two clones were sequenced in comparison with a sequence from EMBL Databank (accession number AF027740) and a conservative mutation in

position 183 was found (a C replacing a T); however, the protein sequence alignment of the 2 clones with that of the reference mPGES-1 submitted in GenBank resulted in a 100% aminoacid identity. A549 cell lines were transfected in order to obtain a stable cell line overexpressing mPGES-1 enzyme. Transfection was performed in cuvettes by Nucleofector II (AMAXA) instrument using Nucleofector Kit T according to the manufacturer's instructions. The recombinant vector pcDNA3.1 (Neomycin resistant) ligated with human mPGES-1 was used for transfection. Transfection efficiency was assessed transfecting cells with a GFP (green fluorescent protein)-expressing vector and checking cell fluorescence by fluorescence microscopy after 4 and 24 h from transfection. After 48 h the medium was replaced with medium containing 400µg/ml G418 (neomycin) as selecting agent. Cells were grown until neomycin selection in untransfected cells was confirmed. Clones were amplified and subsequently tested for mPGES-1 expression by Western blot [19] and for PGE₂ production by a validated radioimmunoassay [17]. Clone D8L was selected for its mPGES-1 high expression level.

2.3. Preparation of human mPGES-1-containing microsomal fraction

A549 and A549/human mPGES-1 (A549 clone D8L) cells maintained in culture were centrifuged, washed once with PBS and suspended at 10×10^6 cells/ml in lysis buffer [TrisHCl 15mM; sucrose 0.25M; EDTA 0.1mM; phenylmethylsulfonyl fluoride (PMSF) 2mM; Aprotinin 10µg/ml; Leupeptin 25µg/ml; glutathione 1mM]. The samples were kept on ice for 10 minutes. Then, the cells were lysed by 4 x 30 seconds sonication pulses in a BANDELIN Soniplus sonifier at 70% of maximum power, frequency 9. Cell debris was removed by centrifugation at 10 000g for 15 minutes at 4°C. The supernatant was centrifuged at 250 000g for 1 h and the membrane pellets were finally suspended in 0.1ml of PGEG plus buffer (i.e. potassium phosphate, 10mM, pH 7, glycerol, 20%, EDTA, 0.1mM, glutathione, 1mM) containing PMSF 2mM, Aprotinin 10µg/ml, Leupeptin 25µg/ml, for each milliliter of lysis buffer. Total protein amount was determined by the Bradford method (Bio-Rad Protein Assay) according to the manufacturer's instructions. Microsomal

preparations were stored at -80°C until used. The presence of the mPGES-1 protein in the microsomal preparation was confirmed by Western blot technique (Figure 3A).

2.4. Inhibition of recombinant human mPGES-1

Aliquots of microsomal preparation from mPGES-1-overexpressing A549 clone D8L (30 µg/ml protein concentration) were used for assessing the enzymatic activity using MultiPROBE II Automated Liquid Handling System (Perkin Elmer, Waltham, MA, USA) in the presence of 2.5mM reduced glutathione and 10µM PGH₂ substrate.

AF3442 (0.01-10µM) was pre-incubated with reaction mixture containing microsomal preparation for 15 minutes at 4°C. Reaction was started by substrate addition (PGH₂) and stopped after 5 minutes at 4°C with 100µl of stop solution (40mM ferric chloride and 0.4mM citric acid). Samples were then subjected to PGE₂ quantification by previously described radioimmunoassay technique [17]. MK-886 (0.1-100µM), an inhibitor of MAPEG proteins, such as leukotriene C₄ synthase and 5-lipoxygenase activating protein (FLAP), affecting mPGES-1 activity at higher concentrations [20, 21] was assessed, as positive control.

2.5. Isolation of human monocytes and pharmacological treatment

Human monocytes were separated from buffy coat by Ficoll-Paque, as previously described [17]. The contribution of COX-1 to prostanoid biosynthesis was minimized by pretreating the buffy coat with aspirin (300µM). Mononuclear cell layer (obtained by Ficoll-Hypaque density gradient centrifugation) was treated with EDTA (2mM) for 15 minutes at 37°C to remove platelets specifically adherent to the monocytes [22]. Cell suspensions routinely contained >90% monocytes [17]. Monocytes (1.5-2x10⁶ cell/ml) cultured in RPMI-1640 supplemented with 0.5% (v/v) of FCS, 1% (v/v) penicillin/streptomycin and L-glutamine (2mM), were incubated with LPS (10µg/ml) (derived from Escherichia Coli 026:B6) at 37°C for 24 h in the presence of DMSO vehicle or increasing concentrations (0.01-100µM) of the mPGES-1 inhibitor, AF3442. This compound was dissolved in DMSO and 2µl of vehicle or stock solution was added to 1ml of cell suspension. PGE₂,

TXB₂ (the stable hydrolysis product of TXA₂), PGF_{2α} and 6-keto-PGF_{1α} (the hydrolysis product of PGI₂) levels were measured in cell culture media by previously described and validated radioimmunoassay techniques [17, 19, 23], while COX-2, COX-1, mPGES-1, mPGES-2, cPGES, TXS and PGIS protein levels were evaluated in cell lysates by previously described Western blot techniques [17, 19].

2.6. Isolation of human platelets

Platelet-rich plasma was prepared by centrifugation of citrated blood at 200g for 15 minutes and platelets were isolated from plasma as previously described [24, 25] and resuspended in RPMI-1640 supplemented with 0.5% (v/v) FCS. Platelet suspensions (5x10⁸/ml; containing <1 leukocyte per 10 000 platelets) were analyzed for the levels of COX-2, COX-1, mPGES-1, mPGES-2, cPGES and TXS in cell lysates by Western blot technique [17, 19].

2.7. Effects of AF3442 on prostanoid generation in human whole blood

Whole blood was drawn from 13 healthy volunteers (age range: 23-35 years). The study was approved by the local Ethics Committee and informed consent was obtained from each subject. The inhibitory effect towards constitutive PGE₂ generation was assessed by evaluating PGE₂ levels generated in whole blood allowed to clot for 60 minutes at 37°C. In clotting whole blood, PGE₂ is mainly produced by platelets in response to endogenously generated thrombin through the activity of COX-1 [23-26] and cPGES and/or mPGES-2. In fact, mPGES-1 is not detectable in platelets (Figure 2). The parallel measurement of TXB₂ (the major product of endogenous AA metabolism in platelets), PGF_{2α} and 6-keto-PGF_{1α} was performed to verify a possible off-target effect of AF3442 on COX-1. The effects of AF3442 on inducible PGE₂ generation were studied by assessing the levels of PGE₂ produced in heparinized human whole blood stimulated for 24 h with LPS (10μg/ml), a stimulus for the induction of both COX-2 and mPGES-1 in monocytes [17, 27]. The simultaneous measurements of TXB₂, PGF_{2α} and 6-keto-PGF_{1α} were performed to verify the impact of AF3442 on COX-2 and the possible redirection of the accumulated PGH₂ substrate towards other PG synthases. For the assessment of the effects on constitutive PGE₂ generation, peripheral venous

blood samples were drawn from healthy volunteers when they had not taken any NSAID during the 2 weeks preceding the study. For the assessment of the effects on LPS-induced PGE₂ generation, heparinized peripheral venous blood samples were drawn from the same subjects pretreated with 300mg aspirin 48 h before sampling to suppress the contribution of platelet COX-1 activity. Different concentrations (0.001-100μM) of AF3442 or DMSO vehicle (2μl) were incubated with whole blood samples and then allowed to clot at 37°C for 1 h or with heparinized whole blood samples in the presence of LPS (10μg/ml) at 37°C for 24 h. Prostanoids were measured in serum or plasma by previously described and validated radioimmunoassays [17, 19, 23]. In these assays the least detectable concentration was 1-2 pg/ml for all prostanoids.

2.8. Western blot analysis

Microsomal fractions or cell lysates samples were loaded (30 or 25-50 μg/lane, respectively) onto 4-15% SDS- PAGE and transferred to PVDF membrane. Membranes were saturated with a solution of 5% non-fat milk in tris-buffered saline-0.1% Tween-20 (TBS-Tween-20), and then incubated with anti-COX-2, anti-COX-1, anti-mPGES-1, anti-mPGES-2, anti-cPGES, anti-TXS, anti-PGIS, or anti-β-actin polyclonal antibodies for 1 h at room temperature [19]. Then, the membranes were washed in TBS-Tween-20 and incubated with the secondary antibodies: anti-goat peroxidase-conjugated IgG for β-actin or anti-rabbit peroxidase-conjugated IgG for the other proteins. Finally, the membranes were washed in TBS-Tween-20 and then all blots were developed by using ECL plus detection according to the manufacturer's instructions.

2.9. Statistical Analysis

Results are expressed as mean±SEM. For the experiments of LPS-stimulated monocytes and whole blood, the production of PGE₂, TXB₂, PGF_{2α} and 6-keto-PGF_{1α} was subtracted from the levels of the prostanoids measured in the presence of vehicle (DMSO). Statistical analysis was performed with Student's t test or one-way ANOVA and Newman-Keuls multiple comparison test, using GraphPad InStat (version 3.00 for Windows). Values of P<0.05 were considered statistically

significant. Concentration-response curves were fitted (using PRISM, GraphPad, version 5.00 for
Windows, San Diego, CA) and IC₅₀ values were reported.

3. Results

3.1. Effect of AF3442 on human recombinant mPGES-1

As shown in Figure 3B, AF3442 caused a concentration-dependent inhibition of PGE₂ generation by human recombinant mPGES-1 with an IC₅₀ of 0.06 μM. In the same microsomal preparation, MK-886, used as a positive control, inhibited PGE₂ generation with an IC₅₀ value of 4.1 μM (not shown), a comparable value to that found by Mancini et al. [20] (IC₅₀: 3.2 μM).

3.2. Expression of COX-isozymes and down-stream synthases and prostanoid generation in LPS-stimulated human monocytes

As shown in Figure 4, in isolated human monocytes stimulated with LPS, COX-2, mPGES-1 were profoundly induced. A slight, but reproducible, increase of cPGES by only 2-fold was detected. In contrast, we detected a constitutive expression of COX-1, TXS, mPGES-2 which was not affected by LPS. PGIS was barely detectable (Figure 4). The spectrum of prostanoid generation (TXB₂, PGE₂, PGF_{2α} and 6-keto-PGF_{1α}) in monocytes both unstimulated and LPS-stimulated is reported in the Table. LPS caused a significant increase of their generation. TXB₂ was the major product of AA (increased by 370-folds) while 6-keto-PGF_{1α} was the minor one (increased by 10-folds). PGE₂ and PGF_{2α} were increased at a similar extent (120-folds) (Table).

3.3. Effects of AF3442 on prostanoid generation in LPS-stimulated human monocytes

Incubation of LPS-stimulated monocytes for 24 h with AF3442 caused a concentration-dependent reduction of PGE₂ biosynthesis with an IC₅₀ value of 0.41 μM (Figure 5). At 1 μM, AF3442 caused an inhibitory effect of 61±3.3% (P<0.01 versus DMSO vehicle) without significantly affecting the other prostanoids (TXB₂, PGF_{2α} and 6-keto-PGF_{1α}: 25.1±5.1%, 21.1±4.1%, 14.8±4.8% of inhibition, respectively) (Figure 5). Similar effects were found at 10 μM. In contrast, at 100 μM, we detected a higher reduction in the biosynthesis of PGE₂ (71.2±2.4%, P<0.05 versus 1 and 10 μM) (Figure 5). This additional inhibitory effect of PGE₂ was associated with a significant reduction of TXB₂ generation of 54.7±5.5% (P<0.01 versus DMSO vehicle). A lower reduction, but not

significant, was detected for $\text{PGF}_{2\alpha}$ and 6-keto- $\text{PGF}_{1\alpha}$ ($38.0 \pm 8.9\%$ and $29.0 \pm 8.8\%$, respectively) (Figure 5).

These data suggest a selective, but incomplete, inhibitory effect of AF3442 on mPGES-1 activity up to $10 \mu\text{M}$. At $100 \mu\text{M}$, PGE_2 reduction was associated with an inhibitory effect on TXB_2 suggesting a possible off-target effect on COX-2 activity and/or expression.

3.4. Effects of AF3442 on the expression of COX-isozymes and down-stream synthases in LPS-stimulated human monocytes

As shown in Figure 6, AF3442 up to $10 \mu\text{M}$ did not significantly affect the levels of COX-2, COX-1, mPGES-1, mPGES-2, cPGES and TXS. In contrast, at $100 \mu\text{M}$, the compound caused a significant ($P < 0.01$ versus control) reduction only of COX-2 levels by $31.4 \pm 2.6\%$ (assessed as ratio of their optical density normalized to the optical density of β -actin).

3.5. Effects of AF3442 on prostanoid generation in human whole blood assays

To study whether the compound affected mPGES-1 activity even in the presence of plasma proteins, we assessed the effect of AF3442 on prostanoid generation in LPS-stimulated whole blood. Incubation of heparinized whole blood with LPS ($10 \mu\text{g/ml}$) resulted in a significant ($P < 0.01$) enhancement of PGE_2 , TXB_2 , $\text{PGF}_{2\alpha}$ and 6-keto- $\text{PGF}_{1\alpha}$ production (Table). In this experimental model, PGE_2 and TXB_2 were the major prostanoid generated with PGE_2 that was higher than TXB_2 ($P < 0.05$) (Table). As reported in Figure 7A, AF3442 inhibited in a concentration-dependent fashion LPS-induced PGE_2 biosynthesis with an IC_{50} of $29 \mu\text{M}$. This value was 70-fold higher than that found in isolated human monocytes (in the presence of low plasma protein level: 0.5% FCS) suggesting an important binding of the compound to plasma proteins. A significant and selective inhibition of mPGES-1 activity was detected at 10 and $100 \mu\text{M}$ ($38 \pm 14\%$, $P < 0.05$ and $69 \pm 5\%$, $P < 0.01$ versus vehicle, respectively). Up to $100 \mu\text{M}$, the other prostanoids were not significantly affected (Figure 7A).

1 Then, we assessed the impact of AF3442 on thrombin-stimulated prostanoids which are generated
2 mainly from platelet COX-1 and constitutive down-stream synthases. In fact, in platelets inducible
3 COX-2 and mPGES-1 were not detectable (Figure 2). As shown in Figure 7B, the compound did
4 not affect thrombin-stimulated PGE₂ and also other prostanoids.
5
6

7
8 Altogether, these results showed that the compound up to 100μM - causing a clinically relevant
9 degree of inhibition of PGE₂ by approximately 70% - is a selective inhibitor of mPGES-1 in human
10 whole blood.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4. Discussion

Inhibitors of mPGES-1 are potential, novel anti-inflammatory drugs with the possible advantage of not affecting or perhaps causing a beneficial impact on cardiovascular homeostasis [9]. However, redirection of the PGH₂ substrate to other PG synthases in the presence of mPGES-1 deletion has been shown both in vivo and in vitro [8, 14]. This phenomenon might occur at different extent in different cell types, thus, translating into the generation of prostanoids with opposite effects for the cardiovascular system [9]. It is unknown whether this effect occurs also in the presence of an incomplete inhibition of mPGES-1, as it would take place after drug treatment. Thus, we studied the contribution of mPGES-1 to PGH₂ metabolism in LPS-stimulated isolated human monocytes and whole blood in the presence of pharmacological inhibition by the novel mPGES-1 inhibitor, AF3442 [18]. We aimed to explore this effect in human monocytes because: i) they are the target for clinical efficacy; ii) they play a key role in atherogenesis through the generation of PGE₂, a mediator of inflammation, and TXA₂, a potent proaggregatory and vasoconstrictor agent [28]. AF3442 affected LPS-induced mPGES-1 activity of human monocytes even in the presence of plasma proteins, i.e. in whole blood (Figure 7A). In whole blood at 100μM, it caused a clinically relevant degree of inhibition of PGE₂ by approximately 70% which was not associated with any significant change of the biosynthesis of other prostanoids.

AF3442 is a molecule belonging to the carbazole class of compounds [18]. It was very potent towards recombinant human mPGES-1 (IC₅₀: 0.06 μM) and at 1μM, it completely suppressed the enzyme activity. In LPS-stimulated monocytes (in the presence of low concentrations of proteins, i.e. 0.5% FCS), AF3442 1μM caused a maximal, selective inhibition of PGE₂ of 61%. An almost comparable selective degree of inhibition of PGE₂ generation (by 69%) was obtained at 100μM of the compound in LPS-stimulated whole blood which suggests an extensive plasma protein binding by the compound. An important issue is whether this extent of inhibition of LPS-stimulated whole blood PGE₂ by AF3442 might be clinically relevant. We have previously looked at the degree of inhibition of LPS-stimulated whole blood PGE₂ by circulating peak concentrations of therapeutic

doses of several NSAIDs [6]. Our results show that low-dose ibuprofen (1200 mg/day) caused a maximal inhibition of 75% [6]. Moreover, it has been shown that therapeutic plasma concentrations of analgesic doses of NSAIDs correlated with the IC_{80} (drug concentration which inhibits enzyme activity by 80%) for inhibition of LPS-stimulated whole blood PGE_2 production in vitro [15].

Altogether these findings suggest the possible clinical efficacy of AF3442 which should be confirmed by in vivo studies.

Failure of AF3442 to completely suppress inducible PGE_2 generation could be explained by the contribution of other PGES, such as mPGES-2 which may couple to COX-2, to the synthesis of this prostanoid [29]. Alternatively, it is possible that some PGH_2 isomerized to PGE_2 , non-enzymatically [30, 31]. However, in murine macrophages, in presence of deletion of mPGES-1, PGE_2 generation was reduced by more than 90% demonstrating that mPGES-1 activity is a key factor in LPS-induced PGE_2 production, in this cell-type [8, 14].

Unexpectedly, we showed that in the presence of an incomplete suppression of mPGES-1, shunting of COX-2-derived PGH_2 to other prostanoids did not occur. This finding was showed both in whole blood and in isolated monocytes.

In human monocytes, LPS induced the generation of TXB_2 , PGE_2 , $PGF_{2\alpha}$ and extremely low levels of PGI_2 . TXB_2 was the dominant product of monocytes exceeding by 10-fold PGE_2 .

High levels of expression of TXS, together with efficiency of coupling between TXS and COX-2 [32, 33] might be the determinants which contribute to the dominant generation of inducible TXA_2 in isolated monocytes. In fact, it has been shown that TXS efficiently couples to COX-2 when small amounts of AA are gradually supplied over a long period, such as in response to LPS [32, 33]. In this scenario, mPGES-1 is not the dominant pathway of PGH_2 metabolism; thus its inhibition translates into a limited accumulation of PGH_2 which explains our failure to detect redirection towards TXB_2 and other prostanoids. This is different from the results obtained in thioglycollate-elicited peritoneal macrophages stimulated in vitro with LPS [8, 14] showing that PGE_2 is the major prostanoid and deletion of mPGES-1 caused redirection towards TXB_2 and PGI_2 , but TXB_2

predominated. However, Boulet et al. [10] studied the shunting of PGH_2 to alternative prostanoid pathways in the presence of complete and incomplete loss of mPGES-1 gene and they did not detect a significant redirection towards TXB_2 in peritoneal macrophages under similar experimental conditions. The reason of these discrepant results is unclear. It has been suggested that the use of mice with different genetic background might have played a role [14].

We propose that differential expression of influx and efflux transport proteins may influence PGH_2 redirection towards other PG synthases. Excess PGH_2 may be immediately released outside the cell after intracellular biosynthesis - probably through the action of MRP4/ABCC4 (multidrug resistance protein 4 adenosine triphosphate-binding cassette, subfamily C, member 4) [34] or simple diffusion - and then it may be reuptaken, probably via the prostaglandin transporter [35, 36]. Thus, shunting of PGH_2 to other prostanoids may be dependent on the expression of transport proteins in different cell types. This hypothesis will be explored in a specific study.

In order to verify the occurrence of PGH_2 redirection in the presence of mPGES-1 inhibition in a more physiologic system, we studied the effect of AF3442 in LPS-stimulated whole blood where TXB_2 , PGE_2 , $\text{PGF}_{2\alpha}$ and 6-keto- $\text{PGF}_{1\alpha}$ are mainly from monocytes through the activity of induced COX-2 [17]. In this system, PGE_2 is the major prostanoid generated which was only slightly more abundant than TXB_2 (Table). The lower concentration of PGE_2 generated in isolated monocytes versus whole blood may suggest the contribution of extramonocyte mPGES-1 to the generation of PGE_2 in whole blood. In particular, neutrophil mPGES-1, which has been shown to be constitutively expressed [37], might act a part. However, even in whole blood where PGE_2 was the major prostanoid, we did not detect significant redirection of PGH_2 metabolism towards other prostanoids. These results may suggest that accumulated PGH_2 is rapidly released and not reuptaken by blood cells. Released PGH_2 may bind to plasma proteins with avidity thus preventing transcellular metabolism of PGH_2 between blood cells and leading to its degradation.

Deletion of mPGES-1 retards atherogenesis and limits aortic aneurysm formation in hyperlipidaemic mice [8, 9]. However, it does not predispose to thrombogenesis and has a limited

1 impact on blood pressure compared to inhibition of COX-2 [8, 9]. These favourable effects for the
2 cardiovascular system, in the presence of deletion of mPGES-1, may at least in part be due to
3
4 augmented excretion of major metabolites of PGD₂ (PGD-M) and PGI₂ (PGI-M) [8, 9, 38].
5
6 Enhanced synthesis of PGI₂ in mPGES-1 deleted murine macrophages and vascular smooth muscle
7
8 cells in vitro, was found by Wang et al. [8]. We did not confirm this phenomenon in human
9
10 monocytes by the novel mPGES-1 inhibitor in vitro. However, it should be pointed out that in these
11
12 cells PGI₂ was generated at very low-concentrations which is consistent with the very low levels of
13
14 expression of PGIS detected in monocytes (Figure 4). The occurrence of increased biosynthesis of
15
16 PGI₂ in vivo by pharmacological inhibition of mPGES-1 should be verified.
17
18
19 In human monocytes, in the absence of plasma proteins, a concentration of AF3442 100μM, i.e.
20
21 100-fold higher than that causing a maximal inhibition of mPGES-1, was associated with a small
22
23 off-target effect on COX-2 expression. Whether down-regulation of COX-2 levels by 35% involved
24
25 a transcriptional and/or a posttranscriptional mechanism remains to be investigated.
26
27
28 In conclusion, we have demonstrated that a selective mPGES-1 inhibitor reduced monocyte PGE₂
29
30 generation at clinically relevant ranges (i.e. approximately 70%) also in presence of plasma
31
32 proteins. In human monocytes, mPGES-1-dependent PGH₂ metabolism represents a major
33
34 metabolic route of PGE₂ generation, while other PGESs or non-enzymatic formation of PGE₂
35
36 represent minor pathways of this prostanoid biosynthesis. Pharmacological inhibition of mPGES-1
37
38 did not translate into redirection of PGH₂ metabolism towards other terminal PG synthases in
39
40 monocytes. The functional consequences of the phenotype induced by pharmacological inhibition
41
42 of mPGES-1 deserve to be investigated in vivo in suited experimental animals.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgements

This study was supported with a grant by A.C.R.A.F. to Paola Patrignani. The authors wish to thank Dr. Nicola Cazzolla, Dr. Angelo Guglielmotti and Dr. Giuseppe Biondi for revising the manuscript and for excellent scientific assistance.

Footnotes

Conflict of interest

Isabella Coletta, Giorgina Mangano, Maria Alessandra Alisi, Lorenzo Polenzani, Claudio Milanese are employees of A.C.R.A.F. S.p.A., Angelini Research Center who funded this research. Paola Patrignani received a grant by A.C.R.A.F. to perform the study.

References

- [1] Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* 2001; 294:1871-5.
- [2] Kudo I, Murakami M. Prostaglandin E synthase, a terminal enzyme for prostaglandin E₂ biosynthesis. *J Biochem Mol Biol* 2005;38:633-8.
- [3] FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. *N Engl J Med* 2001;345:433-42.
- [4] Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. *J Clin Invest* 2001; 108:7-13.
- [5] Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. *J Clin Invest* 2006;116:4-15.
- [6] García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. *J Am Coll Cardiol* 2008;52:1628-36.
- [7] Patrignani P, Capone ML, Tacconelli S. NSAIDs and cardiovascular disease. *Heart* 2008; 94:395-7.
- [8] Wang M, Zukas AM, Hui Y, Ricciotti E, Puré E, FitzGerald GA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. *Proc Natl Acad Sci* 2006;103:14507-12.
- [9] Wang M, Song WL, Cheng Y, Fitzgerald GA. Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. *J Intern Med* 2008;263:500-5.
- [10] Boulet L, Ouellet M, Bateman KP, Ethier D, Percival MD, Riendeau D, et al. Deletion of microsomal prostaglandin E₂ (PGE₂) synthase-1 reduces inducible and basal PGE₂ production and alters the gastric prostanoid profile. *J Biol Chem* 2004;279:23229-37.

- [11] Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B. Identification of human prostaglandin synthase: a microsomal, glutathione-dependent, inducible enzyme constituting a potential novel drug target. *Proc Natl Acad Sci* 1999;96:7220-5.
- [12] Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. *J Biol Chem* 2000;275:32783-92.
- [13] Sampey AV, Monrad S, Crofford LJ. Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2. *Arthritis Res Ther* 2005;7:114-7.
- [14] Trebino CE, Eskra JD, Wachtmann TS, Perez JR, Carty TJ, Audoly LP. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. *J Biol Chem* 2005;280:16579-85.
- [15] Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. *Rheumatology* 2005;44:846-59.
- [16] Patrignani P, Tacconelli S, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. *Ther Clin Risk Manag* 2008;4:983-97.
- [17] Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. *J Pharmacol Exp Ther* 1994;271:1705-12.
- [18] Alisi A, Cazzolla N, Furlotti G, Dragone P, Russo V, Mangano G, et al. 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof. PCT n. WO2007014687; 2007.
- [19] Di Francesco L, Totani L, Dovizio M, Piccoli A, Di Francesco A, Salvatore T, et al. Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. *Circ Res* 2009;104:506-13.
- [20] Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC, et al. Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. *J Biol Chem* 2001;276:4469-75.

- [21] Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, et al. Inhibitors of the inducible microsomal prostaglandin E₂ synthase (mPGES-1) derived from MK-886. *Bioorg Med Chem Lett* 2005;15:3352-55.
- [22] Praticó D, FitzGerald GA. Generation of 8-epiprostaglandin F₂α by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. *J Biol Chem* 1996;271:8919-24.
- [23] Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. Low dose aspirin and inhibition of thromboxane B₂ production in healthy subjects. *Thromb Res* 1980;17:317-27.
- [24] Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. *J Physiol Pharmacol* 1999;50:661-7.
- [25] Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, Di Francesco L, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. *Circ Res* 2006;98:593-5.
- [26] Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. *J Clin Invest* 1982;69:1366-72.
- [27] Sciulli MG, Seta F, Tacconelli S, Capone ML, Ricciotti E, Pistritto G, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. *Br J Pharmacol* 2003;138:634-41.
- [28] Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Puré E, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. *Circulation* 2005;111:334-42.
- [29] Ueno N, Takegoshi Y, Kamei D, Kudo I, Murakami M. Coupling between cyclooxygenases and terminal prostanoid synthases. *Biochem Biophys Res Comm* 2005;338:70-6.
- [30] Nugteren DH, Christ-Hazelhof E. Chemical and enzymatic conversions of prostaglandin endoperoxide PGH₂. *Adv Prostaglandin Thromboxane Res* 1980;6:129-37.

- [31] Soler M, Camacho M, Escudero JR, Iñiguez MA, Vila L. Human vascular smooth muscle cells but not endothelial cells express prostaglandin E synthase. *Circ Res* 2000;87:504-7.
- [32] Ueno N, Murakami M, Tanioka T, Fujimori K, Tanabe T, Urade Y, et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. *J Biol Chem* 2001;276:34918-27.
- [33] Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. *Prostaglandins Other Lipid Mediat* 2007;82:85-94.
- [34] Skazik C, Heise R, Bostanci Ö, Paul N, Denecke B, Joussen S, et al. Differential expression of influx and efflux transport proteins in human antigen presenting cells. *Exp Dermatol* 2008;17:739-47.
- [35] Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL. Identification and characterization of a prostaglandin transporter. *Science* 1995;268:866-9.
- [36] Park JY, Pillinger MH, Abramson SB. Prostaglandin E₂ synthesis and secretion: the role of PGE₂ synthases. *Clin Immunol* 2006;119:229-40.
- [37] Mosca M, Polentarutti N, Mangano G, Apicella C, Doni A, Mancini F, et al. Regulation of the microsomal prostaglandin E synthase-1 in polarized mononuclear phagocytes and its constitutive expression in neutrophils. *J Leukoc Biol* 2007;82:320-6.
- [38] Wang M, Lee E, Song W, Ricciotti E, Rader DJ, Lawson JA, et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. *Circulation* 2008;117:1302-9.

Legends for figures

Figure 1. Structure of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide]

Figure 2. Expression of COX-isozymes and down-stream synthases in isolated human

platelets. Platelet-rich plasma was prepared by centrifugation of citrated blood at 200g for

15 minutes and platelets were isolated from plasma as previously described [24, 25] and

resuspended in RPMI-1640 supplemented with 0.5% (v/v) FCS (5×10^8 platelets per ml; containing

<1 leukocyte per 10 000 platelets). Platelets were lysed and 25µg of total proteins were analyzed for

COX-1, COX-2, TXS, cPGES, mPGES-2, mPGES-1 and β-actin levels by SDS-PAGE and

Western blot analysis [19]. The blot used for detection of COX-2 was stripped (stripping solution

was from Chemicon International, USA) and reprobed for TXS. β-actin was used as protein loading

control. The figure is representative of 3 different experiments.

Figure 3. Effect of AF3442 on microsomal preparations of A549 (human lung

adenocarcinoma) cell line overexpressing human mPGES-1. (A) Western blot analysis of

mPGES-1 in A549 (human lung adenocarcinoma) cell line and in those transfected with the

recombinant vector pcDNA3.1 (Neomycin resistant) ligated with human mPGES-1 (clone D8L);

(B) inhibitory effect of AF3442 on PGE₂ generation in microsomal preparations of A549 clone

D8L. AF3442 (0.01-10µM) was pre-incubated with reaction mixture containing microsomal

preparations (30 µg/ml protein concentration) for 15 minutes at 4°C, then the reaction was started

by substrate addition (PGH₂) and stopped after 5 minutes at 4°C with 100µl of stop solution (40mM

ferric chloride and 0.4mM citric acid). Samples were then subjected to PGE₂ quantification by

radioimmunoassay. Results were reported as percentage of control (DMSO vehicle) (mean±SEM)

from 3-4 separate experiments.

Figure 4. Expression of COX-isozymes and down-stream synthases in LPS-stimulated human

monocytes. Human monocytes were separated from buffy coat and $1.5-2 \times 10^6$ cell/ml were cultured

in RPMI-1640 supplemented with 0.5% (v/v) FCS and incubated without (saline) or with LPS

(10µg/ml) at 37°C for 24 h. Then, monocytes were lysed and 50µg of total proteins were loaded

onto 4-15% SDS-PAGE and analyzed by Western blot technique for COX-2, COX-1, TXS, cPGES, mPGES-1, mPGES-2, PGIS and β -actin expression. β -actin was used as protein loading control.

The figure is representative of 3 different experiments.

Figure 5. Effects of AF3442 on prostanoid generation in LPS-stimulated human monocytes.

Monocytes were separated from buffy coat which was pretreated with aspirin 300 μ M for 5 minutes to suppress the contribution of COX-1 to prostanoid generation. Increasing concentrations of AF3442 (0.01-100 μ M) or DMSO vehicle were incubated with human monocytes ($1.5-2 \times 10^6$ cell/ml) in the presence of LPS (10 μ g/ml) for 24 h at 37°C. PGE₂, TXB₂, PGF_{2 α} and 6-keto-PGF_{1 α} levels were assayed in culture media by specific radioimmunoassays [17, 19, 23]. Results were reported as percentage of control (DMSO vehicle) (mean $\pm$ SEM) from 3 separate experiments. $\S P < 0.05$, PGE₂ 1 μ M and 10 μ M versus 100 μ M; $**P < 0.01$, PGE₂ 0.01-100 μ M and TXB₂ 100 μ M versus control.

Figure 6. Effects of AF3442 on the levels of COX-isozymes and down-stream synthases in

LPS-stimulated human monocytes. Monocytes ($1.5-2 \times 10^6$ cell/ml) were incubated with LPS (10 μ g/ml) at 37°C for 24 h in the presence of increasing concentrations (0.01-100 μ M) of the mPGES-1 inhibitor, AF3442 or DMSO vehicle. COX-2, COX-1, mPGES-1, mPGES-2, cPGES, TXS and β -actin expression levels were evaluated in monocyte lysates by Western blot techniques. β -actin was used as protein loading control. The figure is representative of 3 different experiments.

Figure 7. Effects of AF3442 on LPS- and thrombin-induced prostanoids in human whole

blood. (A) Effects of AF3442 on prostanoid generation by whole blood COX-2-dependent pathway. Increasing concentrations of AF3442 (0.01-100 μ M) or DMSO vehicle were incubated with 1ml of heparinized human whole blood (drawn from healthy volunteers pre-treated with 300mg aspirin 48 h before sampling to reduce the contribution of platelet COX-1 to prostanoid generation) stimulated with LPS (10 μ g/ml) for 24 h. Parallel assessment of PGE₂, TXB₂, PGF_{2 α} and 6-keto-PGF_{1 α} (by radioimmunoassays) was performed to verify the selective inhibitory effect of the compound

towards mPGES-1 and the possible redirection of PGH₂ metabolism to other PG synthases. Results were reported as % of control (DMSO vehicle) (mean±SEM) from 3 separate experiments.

*P<0.05, PGE₂ (% of control) at AF3442 10µM versus vehicle (DMSO); **P<0.01, PGE₂ (% of control) at AF3442 100µM versus vehicle (DMSO); §P<0.01, PGE₂ versus PGF_{2α}, TXB₂ and 6-keto-PGF_{1α} (% of control), at AF3442 100µM. (B) Effects of AF3442 on prostanoid generation by whole blood COX-1-dependent pathway. AF3442 (0.001-100µM) or DMSO vehicle were incubated with 1ml of whole blood samples (drawn from healthy volunteers who did not take any NSAIDs for 2 weeks before blood collection) that were allowed to clot for 60 minutes to assess in vitro selective inhibiting effect of AF3442 towards COX-1-dependent prostanoids mainly of platelet origin [23, 26]. Since platelets do not express mPGES-1, PGE₂ generation may occur by the activity of cPGES and/or mPGES-2. Thus, this assay allowed to verify the possible effects of the compound towards other PGE synthases. PGE₂, TXB₂, PGF_{2α} and 6-keto-PGF_{1α} levels were measured by specific radioimmunoassays. Results were reported as % of control (DMSO vehicle) (mean±SEM) from 3 separate experiments for AF3442 0.01-100µM and from 2 experiments for AF3442 0.001µM.

Table. Prostanoid levels in LPS-stimulated human monocytes and whole blood.

Prostanoid	Monocytes (ng/10 ⁶ cells)		Whole blood (ng/ml)	
	Saline	LPS	Saline	LPS
TXB ₂	0.080±0.011	29.7±4.90*	0.890±0.240	27.08±3.66**
PGE ₂	0.030±0.005	3.70±0.59*	0.840±0.190	38.37±8.03**§
PGF _{2α}	0.022±0.004	2.69±0.61*	0.500±0.050	5.83±0.64**
6-keto-PGF _{1α}	0.025±0.010	0.30±0.03**	0.005±0.003	0.39±0.09**

Values are reported as mean±SEM (n=3 for monocytes and n=9-13 for whole blood). *P<0.05 and

**P<0.01 versus saline; §P<0.05 versus TXB₂.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7